SCHEMBL5243045

SCHEMBL5243045

O=S(=O)(Oc1ccc(N2CCN(S(=O)(=O)c3ccc(Cl)c4nonc34)CC2)cc1)c1ccc(Cl)c2nonc12

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.50
KMT2A Q03164 5/20 0.50
ALDH1A1 P00352 4/20 0.49
MAPT P10636 7/20 0.47
THRB P10828 2/20 0.44
ALOX15 P16050 1/20 0.43
LMNA P02545 4/20 0.43
TDP1 Q9NUW8 2/20 0.43
ACLY P53396 1/20 0.43
RECQL P46063 1/20 0.41
TSHR P16473 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAPK1 P28482 2/20 0.40
TP53 P04637 1/20 0.40
POLB P06746 1/20 0.40
PKM P14618 1/20 0.40
HSD17B10 Q99714 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5371333 0.84 MEN1 (0.54) MEN1KMT2AALDH1A1MAPTTHRB
SCHEMBL5243664 0.83 ALDH1A1 (0.61) MEN1KMT2AALDH1A1MAPTTHRB
SCHEMBL5243696 0.83 KMT2A (0.72) MEN1KMT2AALDH1A1MAPTTHRB
SCHEMBL5286887 0.76 POLB (0.56) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL5245000 0.75 SMN1; SMN2 (0.52) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL8160491 0.73 ACLY (0.50) MEN1KMT2AALDH1A1MAPTTHRB
SCHEMBL5367281 0.72 MEN1 (0.54) MEN1KMT2AALDH1A1MAPTTHRB
SCHEMBL4786708 0.72 MAPT (0.46) MEN1KMT2AALDH1A1MAPTTHRB
SCHEMBL18711645 0.72 ALDH1A1 (0.55) MEN1KMT2AALDH1A1MAPTTHRB
SCHEMBL5244389 0.72 MEN1 (0.56) MEN1KMT2AALDH1A1MAPTTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 EP claimed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO claimed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO disclosed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282818-A1 Ubiquitin ligase inhibitors NEDD4, TRAF6, XIAP MEN1 3562/4885KMT2A 1303/4885ALDH1A1 2627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.